openPR Logo
Press release

Oncology Biosimilars Market Best Productivity Supply Chain Relationship, Development by 2026 And The Top Companies Are Pfizer Inc., Amgen Inc., Allergan PLC, Mylan N.V., Samsung Bioepis Co. Ltd., Teva Pharmaceutical Industries Ltd.

11-28-2018 12:07 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Biotechnology

Oncology Biosimilars

Oncology Biosimilars

There are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/1305

Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market.

Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth of the oncology biosimilars market over the forecast period

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

Competitive Analysis

Key players operating in the global oncology biosimilars market include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/1305

Oncology Biosimilars Market Taxonomy

By Cancer Type:
Lung Cancer
Colorectal cancer
Cervical Cancer
Breast Cancer
Kidney cancer
Stomach cancer
Brain Cancer
Others

By Product Type:
Monoclonal Antibody
Immunomodulators
Others

By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

North America is expected to dominate the oncology biosimilars market over the forecast period

On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3.

Europe market is also expected to witness rapid growth over the forecast period. This is due to expected launch of major products in the market over the forecast period. Europe-based leading generic manufacturers such as Sandoz (a Novartis International AG’s division) and Mylan N.V. has shown interest in this field. Mylan N.V. has entered into a collaboration agreement with Biocon Limited to develop biosimilars in 2009. The duo got approval for their first biosimilar product in 2017 in U.S. and also, European Medicines Agency (EMA) has accepted resubmission for their Herceptin biosimilar in the same year. With increasing number of approved products, the oncology biosimilars market is expected to witness significant growth in the region over the forecast period.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncology Biosimilars Market Best Productivity Supply Chain Relationship, Development by 2026 And The Top Companies Are Pfizer Inc., Amgen Inc., Allergan PLC, Mylan N.V., Samsung Bioepis Co. Ltd., Teva Pharmaceutical Industries Ltd. here

News-ID: 1404790 • Views: 1143

More Releases from Coherent Market Insights - Biotechnology

Wearable Patch Market 2030 Emerging Trends and Global Demand During the COVID-19 …
Coherent Market Insights published a report, titled,"Wearable Patch Market, by Technology (Connected and Regular), by Application (Monitoring, Drug Delivery, and Diagnostics), by End User (Healthcare and Fitness & Sports), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027." Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial
Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy

All 5 Releases


More Releases for Europe

Synthetic Biology Market – Europe
Synthetic Biology Market Europe is expected to reach USD XX Billion by 2026 from USD XX Billion in 2016 at a CAGR of XX% (Detailed analysis of the market CAGR is provided in the report). Synthetic biology has expanded into various interdisciplinary fields that may be defined as the combination of artificial design and engineering to produce biological systems, chemicals or living organisms. Synthetic biology is also used for improving applications
Europe Wooden Doors Market
Europe Wooden Doors Market https://www.qandqmarketresearch.com/reports/wooden-doors-market-78 This report studies the Wooden Doorsmarket status and outlook of Europe and major countries, from angles of players, countries, product types and end industries; this report analyzes the top players in Europe and major countries, and splits the Wooden Doors market by product type and applications/end industries. The global Wooden Doors market is valued at XX million USD in 2018 and is expected to reach XX million
Europe Radiotherapy Market
The Europe Radiotherapy Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Europe Radiotherapy Market report presents a lucid picture of the current industry landscape, including the historical and projected market size, based
Europe Business Assembly
The Europe Business Assembly (EBA) is an international corporation for the evolution and implementation of economic and social development. The company was established in April 2000 and its history shows a plethora of promising initiatives, creative growth and professional victories. EBA’s activity demonstrates the capabilities and power of professional partnership. The year 2000 saw the beginning and the foundation of EBA with the signing of the memorandum of cooperation and
Smartsourcing in Eastern Europe
In 2008 the outsourcing business of Eastern Europe was estimated at nearly $2 billion, representing just a tiny fraction of the global IT outsourcing market, estimated at about $386 billion. According to the Gartner Dataquest predictions, in the next four years Eastern Europe is expected to outstrip the rest of the offshore market concentrated mainly in the “classical” locations like India. By 2010 Eastern Europe’s IT outsourcing market share is
Home Control conquers Europe
European Home Control Summit attracts participation from leading International companies and organizations 29. February 2008 - Copenhagen/Frankfurt - The first European Wireless Home Control Summit on 9 April 2008, taking place parallel to Light + Building, features leading companies such as Merten, Horstmann, Danfoss, and market researcher Parks Associates as well as publicly funded organizations like the Danish Energy Saving Trust (DEST) presenting the newest trends, products and market strategies pertaining